Edition:
United Kingdom

Pfizer Ltd (PFIZ.NS)

PFIZ.NS on National Stock Exchange of India

3,156.30INR
21 Sep 2018
Change (% chg)

Rs36.20 (+1.16%)
Prev Close
Rs3,120.10
Open
Rs3,148.85
Day's High
Rs3,194.00
Day's Low
Rs2,824.00
Volume
55,546
Avg. Vol
62,506
52-wk High
Rs3,847.70
52-wk Low
Rs1,681.00

Latest Key Developments (Source: Significant Developments)

India's Pfizer Appoints Milind Patil As CFO
Thursday, 16 Aug 2018 

Aug 16 (Reuters) - Pfizer Ltd ::SAYS APPOINTMENT OF MILIND PATIL AS CHIEF FINANCIAL OFFICER.  Full Article

India's Pfizer June-Qtr Profit Rises
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Pfizer Ltd ::JUNE QUARTER NET PROFIT 918.4 MILLION RUPEES VERSUS 571.7 MILLION RUPEES YEAR AGO.JUNE QUARTER REVENUE FROM OPERATIONS 5.12 BILLION RUPEES VERSUS 4.33 BILLION RUPEES YEAR AGO.  Full Article

India's Pfizer March Qtr Profit Rises
Monday, 7 May 2018 

May 7 (Reuters) - Pfizer Ltd ::MARCH QUARTER NET PROFIT 1.05 BILLION RUPEES VERSUS PROFIT OF 680.4 MILLION RUPEES YEAR AGO.MARCH QUARTER REVENUE FROM OPERATIONS 5.20 BILLION RUPEES VERSUS 4.53 BILLION RUPEES YEAR AGO.RECOMMENDED DIVIDEND OF 20 RUPEES PER SHARE.  Full Article

India's Pfizer Dec-Qtr Profit Rises
Wednesday, 24 Jan 2018 

Jan 24 (Reuters) - Pfizer Ltd ::DEC QUARTER NET PROFIT 872.4 MILLION RUPEES VERSUS PROFIT OF 623.7 MILLION RUPEES YEAR AGO.DEC QUARTER REVENUE FROM OPERATIONS 4.57 BILLION RUPEES VERSUS 5.10 BILLION RUPEES YEAR AGO.  Full Article

FDA Approves SGLT2 Inhibitor Steglatro And Fixed-Dose Combination Steglujan For Adults With Type 2 Diabetes
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Merck & Co Inc ::FDA APPROVES SGLT2 INHIBITOR STEGLATRO™ (ERTUGLIFLOZIN) AND FIXED-DOSE COMBINATION STEGLUJAN™ (ERTUGLIFLOZIN AND SITAGLIPTIN) FOR ADULTS WITH TYPE 2 DIABETES.MERCK & CO INC - FDA APPROVED STEGLATRO TABLETS, AN ORAL SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITOR, AND FIXED-DOSE COMBINATION STEGLUJAN TABLETS.MERCK & CO INC - IN ADDITION TO STEGLATRO & STEGLUJAN, FDA ALSO APPROVED FIXED-DOSE COMBINATION SEGLUROMET.  Full Article

Pfizer Sept-qtr profit down about 12 pct
Friday, 10 Nov 2017 

Nov 10 (Reuters) - Pfizer Ltd ::Sept quarter net profit 1.11 billion rupees versus profit of 1.26 billion rupees last year.Sept quarter revenue from operations 5.71 billion rupees versus 5.58 billion rupees last year.  Full Article

BRIEF-India's Pfizer March Qtr Profit Rises

* MARCH QUARTER NET PROFIT 1.05 BILLION RUPEES VERSUS PROFIT OF 680.4 MILLION RUPEES YEAR AGO